Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats.

Creative Commons License

Barış V., Dinçsoy B., Gedikli E., Erdemb A.

Kardiologia polska, vol.79, pp.53-57, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 79
  • Publication Date: 2021
  • Doi Number: 10.33963/kp.15666
  • Journal Name: Kardiologia polska
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.53-57
  • Keywords: empagliflozin, sotalol, QTc prolongation, HEART-FAILURE, RISK, MORTALITY, DISEASE
  • Hacettepe University Affiliated: Yes

Abstract

BACKGROUND Sotalol is a class III antiarrhythmic drug commonly used in various arrhythmia treatments. However, due to its potent potassium channel inhibition, it can prolong the QT interval and lead to malignant arrhythmias. Empagliflozin is an inhibitor of sodium-glucose cotransporter 2 (SGLT2) and has a positive effect on cardiovascular outcomes. Since the effect of empagliflozin on the activation of potassium channels is unknown, there is no recommendation regarding the coadministration of these drugs.